Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Levemir for neurocognitive deficits in bipolar disorder
ACTRN12622000669796Phase 2Completed
- Sponsor
- Swinburne University of Technology
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bipolar disorder (BD) comparing Intranasal Levemir with Matched placebo nasal spray (2 arms). Primary endpoint: Global neurocognitive function. Started Sep 2022; status: completed.
02
Drugs
insulin detemir
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on ACTRN12622000669796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000669796.